Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Third time lucky for also-ran Arzerra

This article was originally published in Scrip

Executive Summary

GlaxoSmithKline/Genmab's Arzerra (ofatumumab) has shown improved progression-free survival (PFS) in a Phase III trial in relapsed chronic lymphocytic leukemia (CLL). The positive interim result in the Phase III PROLONG study comes after recent disappointments in which the CD20-targeting monoclonal antibody failed to improve PFS in a subgroup of patients with the disease (scripintelligence.com, 30 June 2014), while it also failed to meets its PFS target in another trial in diffuse large B-cell lymphoma (scripintelligence.com, 20 May 2014).

Advertisement
Advertisement

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC025974

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel